Il-17a binding proteins
AssigneeCrescendo Biologics Limited
InventorsBryan Edwards, Ulla Lashmar, Brian McGuinness, Mike Romanos, Thomas Sandal, Yumin Teng
Life of this patent
Estimating the term…
Abstract
Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
Claims18
A binding molecule comprising a single domain antibody that binds human IL-17A, said single domain antibody comprising a human heavy chain variable immunoglobulin domain (VH) that comprises a CDR1, a CDR2, and a CDR3 sequence,
- wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:7 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto, or
- wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:251 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto, or
- wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:287 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto, or
- wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:343 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto, or
- wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:347 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto.
(canceled)
4-10. (canceled)
12-17. (canceled)
19-24. (canceled)
26-28. (canceled)
The binding molecule according to claim 27, comprising wherein said CDR1 sequence comprises the amino acid sequence of SEQ ID NO:345 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto;
- and
- vv wherein said CDR2 sequence comprises the amino acid sequence of SEQ ID NO:346 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto.
30-37. (canceled)
A pharmaceutical composition comprising
- a pharmaceutical carrier;
- and
- a binding molecule that binds human IL-17A, said binding molecule comprising a human heavy chain variable immunoglobulin domain (VH) that comprises a CDR1, a CDR2, and a CDR3 sequence,
- wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:7 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto or,
- wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:251 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto, or
- wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:287 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto, or
- wherein said CDR3 sequence comprises the amino acid sequence of SEQ ID NO:343 or an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto, or
- wherein said CDR3 sequence comprises the amino acid sequence of comprising SEQ ID NO:347 or a an amino acid sequence with at least 70%, at least 80%, at least 90%, or at least 95% homology thereto.
41-49. (canceled)
51-61. (canceled)
Dependencies are inferred from the claim text.